vensun pharmaceuticals inc private company information  bloomberg july    am et pharmaceuticals company overview of vensun pharmaceuticals inc snapshot people company overview vensun pharmaceuticals inc a pharmaceutical company develops a portfolio of generic prescription products in various dosage forms for a range of therapeutic categories it engages in codeveloping the products with strategic partners in the united states and overseas the company was incorporated in  and is based in yardley pennsylvania  township line roadsuite yardley pa united statesfounded in  phone  fax  wwwvensunrxcom key executives for vensun pharmaceuticals inc mr hemanshu n pandya chief executive officer president and executive director dr syed e abidi phd chairman mr josh gordon senior vice president of commercial operations mr kamlesh haribhakti chief scientific officer executive vice president and director age  mr dhananjay g wadekar executive vice president and director age  compensation as of fiscal year  vensun pharmaceuticals inc key developments vensun pharmaceuticals inc appoints joan janulis as senior vice president of regulatory affairs and compliance feb   vensun pharmaceuticals inc announced the appointment of joan janulis as the senior vice president of regulatory affairs and compliance in this role ms janulis will oversee the regulatory affairs quality and compliance functions ms janulis was most recently a vice president and head of the regulatory practice at lachman consultants similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target private placement november    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact vensun pharmaceuticals inc please visit wwwvensunrxcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close vensun pharmaceuticals inc completes series c financing  marketwatch bulletin investor alert press release dec    am est vensun pharmaceuticals inc completes series c financing yardley pa dec   business wire  vensun pharmaceuticals inc “vensun” or “the company” a privately held generic pharmaceuticals company today announced the completion of  million series c preferred financing with a consortium of investors led by perceptive advisors llc deerfield management company lp also joins perceptive advisors as a new investor in the company additional investors in the financing include prior investors jw asset management llc company management and associates and entities affiliated with dr allen chao the cofounder of watson pharmaceuticals inc now allergan plc quoteszigmancomposite agn   vensun intends to use the capital for research and development expenses associated with future product development projects as well as working capital needs mr hem pandya president and ceo of vensun commented “we are excited to enter the next phase of our growth story the support and confidence shown by our existing investors and the new series c investors have positioned us well for continued success this financing will enable vensun to transform our development pipeline into approved commercial products and provide us with the flexibility to pursue additional growth opportunities” joseph edelman founder and ceo of perceptive advisors remarked “we are excited to support vensun as it continues to develop a robust product pipeline” michael altman senior analyst at perceptive advisors and newly appointed member to vensun’s board of directors added “vensun is expecting a number of new product approvals over the next several years which position the company for continued growth” jason wild president and chief investment officer of jw asset management and director of vensun stated “as the lead investor in both the series a and series b financings we are excited to strengthen our partnership with vensun through our participation in the series c financing vensun’s management team has established a strong track record and we are delighted to renew our commitment towards their goal of becoming a leading generic pharmaceutical company” leerink partners llc served as financial advisor to vensun in the financing vensun’s legal advisor is goodwin procter llp proskauer rose llp acted as legal counsel for perceptive advisors llc about vensun pharmaceuticals inc vensun pharmaceuticals inc based in yardley pennsylvania was established in july  and is an emerging pharmaceutical company developing a portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories the company is codeveloping the products with a number of strategic partners in the us and overseas the company has four andas approved more than  filed andas and has approximately  products in active development with various partners vensun also inlicensed over  products to expand and diversify its pipeline for more information regarding vensun pharmaceuticals inc please visit wwwvensunrxcom  about perceptive advisors llc founded in  and based in new york ny perceptive advisors is an investment management firm focused on supporting the progress of the life sciences industry by identifying opportunities and directing financial resources to the most promising technologies in healthcare for more information about perceptive advisors visit wwwperceptivelifecom  about jw asset management llc jw asset management a new york based registered investment adviser is active in both public and private equity markets jason wild a registered pharmacist is the firms founder and chief investment officer jw asset management was founded in  and has a strong history of finding opportunities within the specialty pharmaceutical sector about deerfield management company lp deerfield is an investment management firm committed to advancing healthcare through investment information and philanthropy for more information please visit wwwdeerfieldcom this press release does not constitute an offer to sell or the solicitation of an offer to buy any security nor shall there be any sale issuance or transfer of securities of vensun pharmaceuticals inc in any state in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state view source version on businesswirecom httpwwwbusinesswirecomnewshomeen source vensun pharmaceuticals inc vensun pharmaceuticals inc hem pandya president  ceo  wwwvensunrxcom copyright business wire  quoteszigmancomposite add to watchlist agn allergan plc us  us nyse     volume m july   p pe ratio dividend yield market cap billion rev per employee most popular  market extra wall street isn’t ready for a point tumble in the dow industrials  all the companies in jeff bezos’s empire in one large chart  market snapshot sp  nasdaq finish lower after amazon disappointment dow closes at record  marketwatch first take intel earnings have message for amd and nvidia ‘bring it on’  sectorwatch silicon valleys corporatecampus building boom is a cautionary tale find a broker partner center » featured stories seeing america again through new eyes how to dig yourself out of debt move over tesla karma unveils its hybrid sports car the salary you need to afford a home in these  cities why opec will never cut production again log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  vensun pharmaceuticals announces launch of carisoprodol tablets usp  mg employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       vensun pharmaceuticals announces launch of carisoprodol tablets usp  mg tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs yardley pabusiness wirevensun pharmaceuticals inc “vensun” or “the company” a privately held generic pharmaceutical company today announced the launch of carisoprodol tablets usp  mg the first generic equivalent to meda’s soma®  mg tablets according to ims health the product had us sales of approximately  million for the  months ending november   “this is a critical milestone for the company carisoprodol is the first product approval from our development portfolio this marks the first step towards realizing our vision of building an organization that provides affordable and high quality generics while creating value for our customers partners and stakeholders” hem pandya president and ceo said “this is a critical milestone for the company carisoprodol is the first product approval from our development portfolio this marks the first step towards realizing our vision of building an organization that provides affordable and high quality generics while creating value for our customers partners and stakeholders” in addition to this product the company currently markets  products licensed from various partners and has over  accepted anda filings representing  billion in sales for the  months ending november   according to ims health about vensun pharmaceuticals inc vensun pharmaceuticals inc based in yardley pennsylvania was established in july  and is an emerging pharmaceutical company developing a unique portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories the company is codeveloping the products with a number of strategic partners in the us and overseas to leverage economies of scale to efficiently develop products and ultimately supply quality generic products to the marketplace cost effectively the company currently has over  filed andas and has  products in active development in addition to this proprietary product development program vensun has also inlicensed  products to expand and diversify its pipeline for more information regarding vensun pharmaceuticals inc please visit wwwvensunrxcom contacts vensun pharmaceuticals inchem pandyapresident  ceowwwvensunrxcom read at biospacecom related news vensun pharmaceuticals announces appointment of ed schutter to its board of directors congress subpoenas martin shkreli to testify about drug pricing shkreli may plea the fifth vensun pharmaceuticals enters into manufacturing supply and distribution agreement with sciegen pharmaceuticals inc gilead gild faces lawsuits over aids drug patents threats of lawsuits for hepatitis c treatments emails reveal turing valeant vrx price increases were basis for revenue growth off label use of roche rhhby’s avastin in india puts  in the hospital prompts officials to halt using the drug valeant vrx has found another enemy in democratic presidential candidate hillary clinton pfizer pfe jacked up prices of more than  drugs on jan  gilead gild should have investors giddy over continued hcv dominance at jp morgan massive problem martin shkreli zeroedin on is happening again please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • vensun pharmaceuticals   • clinical  drug product news                 microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one vensun pharmaceuticals inc  generic pharmaceutical prescription drugs search phone   township line rd suite  yardley pa  vensun pharmaceuticals inc based in yardley pennsylvania was established in july  and is an emerging pharmaceutical company developing a portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories the company is codeveloping the products with a number of strategic partners in the us and overseas the company has four andas approved more than  filed andas and has approximately  products in active development with various partners vensun also inlicensed over  products to expand and diversify its pipeline products partners news and events careers  vensun pharmaceuticals inc search phone   township line rd suite  yardley pa  careers vensun is always seeking dynamic individuals who have the talent skill set and desire to work in a very high pace environment within the pharmaceutical industry if you are interested in potentially joining the vensun team please email your resume to hrvensunrxcom  if there is a position available that meets the required qualifications we will gladly contact you vensun is an equal opportunity employer news  events  vensun pharmaceuticals inc search phone   township line rd suite  yardley pa  news  events posted on april   by admin c april   ed schutter press release vensun pharmaceuticals appoints ed schutter to its board of directors october   josh gordon press release vensun pharmaceuticals appoints josh gordon as the senior vice president of sales marketing and commercial operations august   vensun sciegen agreement press release vensun pharmaceuticals has entered into manufacturing supply and distribution agreement with sciegen pharmaceuticals to commercialize  prescription generic products  june  vensun pharmaceuticals files its th anda december   vensun series b financing press release vensun pharmaceuticals completes a  million series b financing led by jw asset management llc vensun pharmaceuticals files its th anda august  vensun pharmaceuticals executes a multiproduct development  supply agreement with a bengaluru india based fda approved pharmaceutical company march  vensun pharmaceuticals raises m in a series a financing led by jw asset management the company is now established as a delaware c corp – vensun pharmaceuticals inc february  vensun pharmaceuticals executes a multiproduct development  supply agreement with a leading chennai india based fda approved pharmaceutical company december  vensun pharmaceuticals files its st anda october  vensun pharmaceuticals raises an initial funding of m july  vensun pharmaceuticals executes a multiproduct development and supply agreement with pharmaceutics international inc pii vensun pharmaceuticals llc is established as a rapidly emerging pharmaceutical company developing a unique portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories about us  vensun pharmaceuticals inc search phone   township line rd suite  yardley pa  about us executive management board of directors executive management  vensun pharmaceuticals inc search phone   township line rd suite  yardley pa  executive management hemanshu hem pandya – president and chief executive officer hemanshu hem pandya – president and chief executive officer mr pandya is an experienced pharmaceutical executive with a broad spectrum of commercial operational strategic and corporate development experience previously mr pandya was president and chief executive officer of igi laboratories inc nyse amex ig a provider of topical formulation development analytical manufacturing and packaging services to the pharmaceutical industry prior to igi mr pandya was chief operating officer of nexmed inc now apricus biosciences inc – nasdaq apri responsible for rd operations and corporate development he has also served in various senior management roles within the pharmaceutical industry including senior vice president of business development and strategic alliances for andrx pharmaceuticals now watson pharmaceuticals – nyse  wpi chief commercial officer for putney inc and senior management roles with able laboratories inc ivax pharmaceuticals inc now teva pharmaceuticals industries limited – nyse  teva and fauldingpurepac pharmaceutical company now actavis inc kamlesh haribhakti – executive vice president and chief scientific officer mr haribhakti has extensive experience in all aspects of pharmaceutical development including formulations analytical pharmacokinetics and regulatory mr haribhakti has been responsible for successfully developing filing and obtaining fda approval for over  generic pharmaceutical products previously mr haribhakti was managing director of dinesh remedies limited drl prior to drl mr haribhakti was a cofounder and chief executive officer of kvd pharma until its sale to amneal pharmaceuticals in dec  he has also served in rd roles for several pharmaceutical companies throughout his career including able laboratories inc mcneil pharmaceuticals a johnson  johnson company eon laboratories inc now sandoz a novartis company fauldingpurepac pharmaceutical company now actavis inc and ivax pharmaceuticals inc now teva pharmaceuticals industries limited josh gordon – senior vice president of sales marketing and commercial operations mr gordon is an experienced pharmaceutical executive with a broad array of commercial operational strategic and financial experience mr gordon served in various senior and progressive management roles in the generic pharmaceutical industry including vice presidentgeneral manager specialty pharmaceuticals at hospira senior vice president of purchasing and operations at anda a unit of andrx pharmaceuticals now actavis and vice president of generic product purchasing at cardinal health prior to joining vensun mr gordon was a vice president at baxter international inc in their medical products division mr gordon received his bachelor’s degree from the university of pennsylvania’s wharton school of business he earned a masters of professional accounting degree from the university of miami graduate school of business mr gordon is a certified public accountant joan janulis – senior vice president of regulatory affairs and compliance ms janulis is a highly experienced pharmaceutical executive with extensive knowledge of us food and drug administration fda regulations guidance and best practices ms janulis was most recently a vice president and head of the regulatory practice at lachman consultants a premier pharmaceutical consulting company  she also served on lachman’s board of directors for the past  years prior to joining lachman ms janulis held various executive positions at fauldingpurepac pharmaceutical now actavis inc  nyse act ivax pharmaceuticals inc now teva pharmaceuticals industries limited – nyse  teva and able laboratories ms janulis holds a bachelor of science degree in chemical engineering from the new jersey institute of technology and has maintained a regulatory affairs certification rac for over  years jatin desai phd – executive director rd and technical operations dr desai is an executive with over  years of experience in generic branded and otc product development clinical research and commercialization of products ranging from solid dosage to injectables his area of expertise is in modified release dosage forms dr desai has three granted patents and several additional applications under review previously dr desai was the vice president technical operations at austarpharma prior to austarpharma he served in various senior roles as director of formulation research at zydus pharmaceuticals and vice president technical operations at morepen laboratories dr desai holds a masters of science degree in pharmaceutics and industrial pharmacy from lallubhai motilal college of pharmacy india and a doctorate in pharmaceutics from north gujarat university india donna m cordasco – senior director of quality and compliance ms cordasco has over  years of diverse experience in pharmaceutical rd and quality management  prior to joining vensun ms cordasco was director of laboratory qa for the international aids vaccine initiative a nonprofit organization engaged in novel research and vaccine development  her generic pharmaceutical industry experience includes roles as head of qaqc  regulatory at igi laboratories inc amex ig and director of qaqc at sun pharmaceuticals industries inc while at fauldingpurepac pharmaceutical company now actavis inc – nyse act she served in several senior management roles including director of qc director of analytical services and in various project management strategic planning and process improvement  roles early in her career ms cordasco served as an adjunct professor in organic and biochemistry ms cordasco has a bachelor of science degree in biochemistry from the university of new hampshire and a masters of science degree in biochemistry and molecular biology from new york university george sager – director of operations mr sager has more than  years of financial and operational experience prior to joining vensun mr sager was controller at medicia holdings llc where he managed the daytoday finance and accounting functions for the contract manufacturer serving the health and beauty industry previously mr sager was vice president of finance for glenmark pharmaceuticals and has held various positions with companies such as able laboratories inc lederle laboratories asea brown boveri ivc industries and guerlain inc mr sager holds a mba in finance from fairleigh dickinson university and a bachelor of science degree in accounting from ramapo college rajeev mohan phd – director of strategic development dr mohan has extensive experience in product development scaleup manufacturing business strategy product lifecycle management alliance management and product commercialization prior to joining vensun dr mohan was manager of strategic analytics supporting the sales and marketing team at mutualurl pharma now takeda – nysetkphf including the commercial assessment of business development projects prior to mutual he served in various technical and operational roles including manager of manufacturing systems and cost management at andrx pharmaceuticals inc now actavis – nyseact  dr mohan holds a mba from cornell university a doctorate in chemical engineering from polytechnic university nyu and a bachelor of science degree in chemical engineering from osmania university india vensun pharmaceuticals inc  generic pharmaceutical prescription drugs search phone   township line rd suite  yardley pa  vensun pharmaceuticals inc based in yardley pennsylvania was established in july  and is an emerging pharmaceutical company developing a portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories the company is codeveloping the products with a number of strategic partners in the us and overseas the company has four andas approved more than  filed andas and has approximately  products in active development with various partners vensun also inlicensed over  products to expand and diversify its pipeline products partners news and events products  vensun pharmaceuticals inc search phone   township line rd suite  yardley pa  products   available products click product name below for prescribing information product strength brand reference ndc packaging size sildenafil tablets usp  mg revatio® tablets   count bottle carisoprodol tablets usp civ  mg soma® tablets   count bottle carisoprodol tablets usp civ  mg soma® tablets     count bottle  count bottle  count bottle clopidogrel tablets usp  mg plavix® tablets      count bottle  count bottle  count bottle  count bottle donepezil hydrochloride tablets usp  mg    mg aricept® tablets        count bottle  count bottle  count bottle  count bottle  count bottle  count bottle fluoxetine capsules usp  mg  mg   mg prozac® capsules         count bottle  count bottle  count bottle  count bottle  count bottle  count bottle  count bottle hydrochlorothiazide tablets usp  mg  mg hydrochlorothiazide tablets    count bottle  count bottle levocetirizine dihydrochloride tablets  mg xyzal® tablets   count bottle metoprolol tartrate tablets usp  mg  mg  mg metoprolol tartrate tablets usp        count bottle  count bottle  count bottle  count bottle  count bottle  count bottle nystatin topical powder usp  usp units per gram nystatin topical powder     gram bottle  gram bottle  gram bottle pramipexole dihydrochloride tablets  mg  mg  mg  mg  mg  mg mirapex® tablets        count bottle  count bottle  count bottle  count bottle  count bottle  count bottle pharmacists doctors and customers for questions about vensun products or to report product complaints or adverse events contact  or complaintsvensunrxcom customers for questions about purchase orders contact customer service  or customerservicevensunrxcom contact us  vensun pharmaceuticals inc search phone   township line rd suite  yardley pa  contact us   pharmacists doctors and customers for questions about vensun products or to report product complaints or adverse events contact  or complaintsvensunrxcom customers for questions about purchase orders contact customer service  or customerservicevensunrxcom   mr hem pandya president  ceo – hpandyavensunrxcom mr kamlesh haribhakti evp  cso – kharibhaktivensunrxcom mr george sager director of operations – gsagervensunrxcom business development team – bdvensunrxcom human resources – hrvensunrxcom investor relations – irvensunrxcom corporate office main telephone number –  fax number –   township line road suite  yardley pa  sales office   carnegie center drive suite  princeton nj    vensun pharmaceuticals inc completes series c financinghomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballvensun pharmaceuticals inc completes series c financingbusiness wiredecember  reblogsharetweetshareyardley pabusiness wirevensun pharmaceuticals inc “vensun” or “the company” a privately held generic pharmaceuticals company today announced the completion of  million series c preferred financing with a consortium of investors led by perceptive advisors llc deerfield management company lp also joins perceptive advisors as a new investor in the company additional investors in the financing include prior investors jw asset management llc company management and associates and entities affiliated with dr allen chao the cofounder of watson pharmaceuticals inc now allergan plc agn vensun intends to use the capital for research and development expenses associated with future product development projects as well as working capital needsmr hem pandya president and ceo of vensun commented “we are excited to enter the next phase of our growth story the support and confidence shown by our existing investors and the new series c investors have positioned us well for continued success this financing will enable vensun to transform our development pipeline into approved commercial products and provide us with the flexibility to pursue additional growth opportunities”joseph edelman founder and ceo of perceptive advisors remarked “we are excited to support vensun as it continues to develop a robust product pipeline” michael altman senior analyst at perceptive advisors and newly appointed member to vensun’s board of directors added “vensun is expecting a number of new product approvals over the next several years which position the company for continued growth”jason wild president and chief investment officer of jw asset management and director of vensun stated “as the lead investor in both the series a and series b financings we are excited to strengthen our partnership with vensun through our participation in the series c financing vensun’s management team has established a strong track record and we are delighted to renew our commitment towards their goal of becoming a leading generic pharmaceutical company”leerink partners llc served as financial advisor to vensun in the financing vensun’s legal advisor is goodwin procter llp proskauer rose llp acted as legal counsel for perceptive advisors llcabout vensun pharmaceuticals incvensun pharmaceuticals inc based in yardley pennsylvania was established in july  and is an emerging pharmaceutical company developing a portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories the company is codeveloping the products with a number of strategic partners in the us and overseas the company has four andas approved more than  filed andas and has approximately  products in active development with various partners vensun also inlicensed over  products to expand and diversify its pipelinefor more information regarding vensun pharmaceuticals inc please visit wwwvensunrxcomabout perceptive advisors llcfounded in  and based in new york ny perceptive advisors is an investment management firm focused on supporting the progress of the life sciences industry by identifying opportunities and directing financial resources to the most promising technologies in healthcare for more information about perceptive advisors visit wwwperceptivelifecomabout jw asset management llcjw asset management a new york based registered investment adviser is active in both public and private equity markets jason wild a registered pharmacist is the firms founder and chief investment officer jw asset management was founded in  and has a strong history of finding opportunities within the specialty pharmaceutical sectorabout deerfield management company lpdeerfield is an investment management firm committed to advancing healthcare through investment information and philanthropyfor more information please visit wwwdeerfieldcomthis press release does not constitute an offer to sell or the solicitation of an offer to buy any security nor shall there be any sale issuance or transfer of securities of vensun pharmaceuticals inc in any state in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such stateview source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nextshkreli portrayed as con prodigy at securities fraud trialassociated pressthis will be in everyones household by banyan hillsponsoredhow fentanyl is making the opioid epidemic even worsevoxjury to soon begin deliberations in pharma bro martin shkrelis fraud trialfortunemartin shkrelis lawyer says former drug company chairman tried to seduce the pharma brocnbcengineer finds pattern makes millions in stocksmoney morningsponsoredthe senate probe into big pharmas hand in the opioid crisis just got biggerbusiness insiderthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderhere are the us targets north korea most likely wants to nukebusiness insiderdiscover it  out of  avg by k customersdiscover cardsponsoredthe real reason overseas manufacturing is coming to americayahoo financecryptocurrency icos are making bitcoin startups richer than vcs ever didfortunechevron and exxon mobil have a tough path ahead nyse traderyahoo finance videowhats the problem with joel osteenchurchleaderscomsponsoredstocks mixed after heavy earnings weekapnewsbreak yellowstone park cracks down on sex harassmentassociated pressstruggling to govern trump faces growing republican uneasestuart actually this is the best our country can do right now if the republicans accomplished anything it would be tax cuts for the wealthy cuts to medicaid medicare and social security removal of all banking regulations and environmental protections and on and on get rid of these traitors in  so our country can be great againjoin the conversation  k